The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer

Critical Reviews in Oncology/Hematology

Volumn 87, Issue 3, 2013, Pages 283-305

  Torino, Francesco ^a   Sarmiento, Roberta ^b   Gasparini, Giampietro ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Bevacizumab; Cetuximab; Neoadjuvant treatment; Rectal cancer; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ABSCESS; ACNE; ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ALOPECIA; ANAL PAIN; ANASTOMOSIS LEAKAGE; ANEMIA; ANGINA PECTORIS; ANOREXIA; ANTIANGIOGENIC THERAPY; ANUS DISEASE; ANUS FISTULA; ASTHENIA; BLOOD TOXICITY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLITIS; COLORECTAL CANCER; CONSOLIDATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CYSTITIS; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENTEROCUTANEOUS FISTULA; EXTERNAL BEAM RADIOTHERAPY; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FISTULA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HEMATOMA; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; ILEITIS; ILEUS; INDUCTION CHEMOTHERAPY; INFECTION; INTESTINAL BLEEDING; INTESTINE PERFORATION; LETHARGY; LEUKOPENIA; LIVER TOXICITY; LOCALLY ADVANCED RECTAL CANCER; LUNG DISEASE; LUNG EMBOLISM; LUNG INFECTION; LYMPHOCYTOPENIA; METABOLIC DISORDER; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUROGENIC BLADDER; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; OCCLUSION; OPERATIVE BLOOD LOSS; OVERALL SURVIVAL; PAIN; PELVIC DISEASE; PELVIC HEMATOMA; PELVIC INFLAMMATORY DISEASE; PELVIS ABSCESS; PERIANAL INFECTION; PERIANAL PAIN; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHARMACOGENOMICS; PNEUMOTHORAX; POSTOPERATIVE INFECTION; PREOPERATIVE CHEMORADIOTHERAPY; PREOPERATIVE RADIOTHERAPY; PROCTALGIA; PROCTITIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIATION DERMATITIS; RECTOVAGINAL FISTULA; RECTUM CANCER; RECTUM HEMORRHAGE; REOPERATION; REVIEW; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SYSTEMIC DISEASE; TENESMUS; THROMBOCYTOPENIA; TUMOR REGRESSION; URINARY TRACT DISEASE; UROGENITAL TRACT DISEASE; WOUND COMPLICATION; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

BEVACIZUMAB; CETUXIMAB; NEOADJUVANT-TREATMENT; RECTAL CANCER; TARGETED THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84881669674     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.02.002     Document Type: Review

References (153)

1. [accessed 27.07.12]. http://seer.cancer.gov/csr/1975_2009_pops09/.
2. Gerard J.P., Conroy T., Bonnetain F., et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. Journal of Clinical Oncology 2006, 24:4620-4625.
3. Bosset J.F., Collette L., Calais G., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. New England Journal of Medicine 2006, 355:1114-1123.
4. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative CRT for rectal cancer. New England Journal of Medicine 2004, 351:1731-1740.
5. Bosset J.F., Calais G., Mineur L., et al. Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. Journal of Clinical Oncology 2005, 23:5620-5627.
6. Wollman R., Yahalom J., Maxy R., Pinto J., Fuks Z. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. International Journal of Radiation Oncology, Biology, Physics 1994, 30:91-98.
7. Bonner J., Harari P., Giralt J., et al. Radiotherapy plsu cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine 2006, 354:567-578.
8. Giralt J., de las Heras M., Cerezo L., et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer terated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiotherapy and Oncology 2005, 74:101-108.
9. Kim J.-S., Kim J.-M., Li S., et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanmced rectal cancer patients treated with preoperative chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics 2006, 66:195-200.
10. Koop R., Rothbauer E., Mueller E., Schildberg F.W., Jauch K.W., Pfeiffer A. Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels. Diseases of the Colon and Rectum 2003, 46:1391-1399.
11. van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New England Journal of Medicine 2009, 360:1408-1417.
12. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine 2004, 351:337-345.
13. van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared to best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 2007, 25:1658-1664.
14. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Journal of Clinical Oncology 2010, 28:4697-4705.
15. Van Cutsem E., Köhne C.H., Láng I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology 2011, 29:2011-2019.
16. Marchetti A., Gasparini G. K-RAS and cetuximab in colorectal cancer. New England Journal of Medicine 2009, 360:833-834.
17. Bertolini F., Chiara S., Bengala C., et al. Neoadjuvant treatment with single-agent cetuximab followed by f-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. International Journal of Radiation Oncology, Biology, Physics 2009, 73:466-472.
18. Machiels J.P., Sempoux C., Scalliet P., et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Annals of Oncology 2007, 18:738-744.
19. Velenik V., Ocvirk J., Oblak I., Anderluh F. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. European Journal of Surgical Oncology 2010, 36:244-250.
20. Rodel C., Arnold D., Hipp M., et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. International Journal of Radiation Oncology, Biology, Physics 2008, 70:1081-1086.
21. McCollum A.D., Kocs D.M., Chada P., et al. A randomized phase II trial of preoperative chemoradiotherapy with or without cetuximab in locally advanced adenocarcinoma of the rectum. Journal of Clinical Oncology 2010, 28:15s. abstr 3635.
22. Kim S.Y., Hong Y.S., Kim D.Y., et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study. International Journal of Radiation Oncology, Biology, Physics 2011, 81:677-683.
23. Horiseberger K., Treschl A., Mai S., et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. International Journal of Radiation Oncology, Biology, Physics 2009, 74:1487-1493.
24. Dewdney A., Cunningham D., Tabernero J., et al. Multicenter randomized phase ii clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high risk recatl cancer (EXPERT-C). Journal of Clinical Oncology 2012, 30:1620-1627.
25. Pinto C., Di Fabio F., Maiello E., et al. Phase II study of panitumumab, oxaliplatin, 5-fluoruracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Annals of Oncology 2011, 22:2424-2430.
26. Williams K.J., Telfer B.A., Stratford I.J., Wedge S.R. ZD1839 ("Iressa"), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. British Journal of Cancer 2002, 86:1157-1161.
27. Fisher G., Kuo T., Cho C., et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. Journal of Clinical Oncology 2005, 23:5613-5619.
28. Gelibter A.J., Gamucci T., Pollera C.F., et al. A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. Current Medical Research and Opinion 2007, 23:2117-2123.
29. Czito B., Willett C., Bendell J., et al. Increased toxicity with gefitinib, capecitabine and radiation therapy in pancreatic and rectal cancer. Phase I trial results. Journal of Clinical Oncology 2006, 24:656-662.
30. Valentini V., De Paoli A., Gambacorta M.A., et al. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092). International Journal of Radiation Oncology, Biology, Physics 2008, 72:644-649.
31. Hyodo I., Doi T., Endo H., et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. European Journal of Cancer 1998, 34:2041-2045.
32. Nanashima A., Ito M., Sekine I., et al. Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers. Digestive Diseases and Sciences 1998, 43:2634-2640.
33. Chin K., Greenman J., Gardiner E., Kumar H., Topping K., Monson J. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. British Journal of Cancer 2000, 83:1425-1431.
34. Gasparini G., Longo R., Toi M., Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nature Clinical Practice. Oncology 2005, 2:562-577.
35. Allegra C.J., Yothers G., O'Connell M.J., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. Journal of Clinical Oncology 2011, 29:11-16.
36. Cascinu S., Garziano F., Catalano V., et al. An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. British Journal of Cancer 2002, 86:744-749.
37. Lee C., Heijin M., di Tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Caner Research 2000, 60:5565-5570.
38. Kozin S.V., Boucher Y., Hicklin D.J., Bohlen P., Jain R.K., Suit H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Research 2001, 61:39-44.
39. Tong R., Boucher Y., Kozin S., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockage induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Research 2004, 64:373-376.
40. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
41. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine 2004, 10:145-147.
42. Willett C.G., Boucher Y., Duda D.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. Journal of Clinical Oncology 2005, 23:8136-8139.
43. Willett C., Duda D., DiTomaso E., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and 5-fluorouracil in rectal cancer: A multidisciplinary phase II study. Journal of Clinical Oncology 2009, 27:3020-3026.
44. Crane C.H., Eng C., Feig B.W., et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. International Journal of Radiation Oncology, Biology, Physics 2010, 76:824-830.
45. Velenik V., Ocvirk J., Music M., et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiation Oncology 2011, 6:105.
46. Martinez Villacampa M., Capdevila J., Manzano J.L., et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer. Journal of Clinical Oncology 2012, 30(Suppl.). abstr 3571.
47. Marijnen C.A., Rutten H., de Wilt H., et al. Preoperative CRT regimen with capecitabine and bevacizumab in locally advanced rectal cancer: A feasibility study of the Dutch Colorectal Cancer Group (DCCG). Journal of Clinical Oncology 2008, 26(20 Suppl.):abstr15040.
48. Resch G., De Vries A., Öfner D., et al. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer - a two stage phase II clinical trial. Radiotherapy and Oncology 2012, 102:10-13.
49. Gasparini G., Torino F., Ueno T., et al. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 2012, 15:141-150.
50. Czito B.G., Bendell J.C., Willett C.G., et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. International Journal of Radiation Oncology, Biology, Physics 2007, 68:472-478.
51. Kennecke H., Berry S., Wong R., et al. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. European Journal of Cancer 2012, 48:37-45.
52. Hoehler T., Dellas K., Riesenbeck D., et al. Preoperative chemoradiation (CRT) with concurrent capecitabine (Cap), oxaliplatin (Ox), and bevacizumab (Bev) in patients with locally advanced rectal cancer (RC): effects on pathological complete response (pCR) and surgical complications. Journal of Clinical Oncology 2011, 29(Suppl.). abstr 3630.
53. Nogué M., Salud A., Vicente P., et al. AVACROSS Study Group. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based CRT in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 2011, 16:614-620.
54. Dipetrillo T., Pricolo V., Lagares-Garcia J., et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. International Journal of Radiation Oncology, Biology, Physics 2012, 82:124-129.
55. Habr-Gama A., Perez R.O., Sabbaga J., Nadalin W., São Julião G.P., Gama-Rodrigues J. Increasing the rates of complete response to neoadjuvant chemoradiation for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Diseases of the Colon and Rectum 2009, 52:1927-1934.
56. Liang J.T., Lai H.S., Cheng K.W. Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX. Surgical Endoscopy 2011, 25:305-308.
57. Schrag D., Weiser M.R., Goodman K.A., et al. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. Journal of Clinical Oncology 2010, 28(15 Suppl.):abstr3511.
58. Glynne-Jones R., Anyamene N., Moran B., Harrison M. Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation?. Annals of Oncology 2012, 10.1093/annonc/mds010.
59. Hecht J.R., Mitchell E., Chidiac T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. Journal of Clinical Oncology 2009, 27:672-680.
60. Elvira G., Torrecillas L., Cervantes G., Erzao Valle Solis A.A. Phase II study of bevacizumab and cetuximab as neoadjuvant treatment in locally advanced rectal cancer: a preliminary security report. Journal of Clinical Oncology 2011, 29(Suppl. 4). abstr 627.
61. Blaszkowsky L.S., Hong T.S., Zhu A.X., et al. A phase I/II study of bevacizumab, erlotinib, and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Journal of Clinical Oncology 2009, 27(15S). abst 4106.
62. Wadlow R.C., Ryan D.P. The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer 2010, 116:3537-3548.
63. Cunningham D., Atkin W., Lenz H.J., et al. Colorectal cancer. Lancet 2010, 375:1030-1047. 10.1016/S0140-6736(10)60353-4.
64. Sauer R., Liersch T., Merkel S., et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. Journal of Clinical Oncology 2012, 30:1926-1933.
65. Van Gijn W., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncology 2011, 12:575-582.
66. Maas M., Nelemans P.J., Valentini V., et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncology 2010, 11:835-844.
67. Longo R., Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemotherapy and Pharmacology 2007, 60:151-170.
68. Jubb A.M., Harris A.L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncology 2010, 11:1172-1183.
69. Abajo A., Boni V., Lopez I., et al. Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. British Journal of Cancer 2012, 107:287-290.
70. Sleijfer S., Gorlia T., Lamers C., et al. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. British Journal of Cancer 2012, 107:639-645.
71. Duda D.G., Cohen K.S., di Tomaso E., et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. Journal of Clinical Oncology 2006, 24:1449-1453.
72. Debucquoy A., Haustermans K., Daemen A., et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. Journal of Clinical Oncology 2009, 27:2751-2757.
73. Debucquoy A., Machiels J.P., McBride W.H., Haustermans K. Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation. Clinical Cancer Research 2010, 16:2709-2714.
74. Patel U.B., Brown G., Rutten H., et al. Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Annals of Surgical Oncology 2012, 19:2842-2852.
75. Park I.J., You Y.N., Agarwal A., et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. Journal of Clinical Oncology 2012, 30:1770-1776.
76. Nougaret S., Rouanet P., Molinari N., et al. MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy. Radiology 2012, 263:409-418.
77. Barbaro B., Vitale R., Valentini V., et al. Diffusion-weighted magnetic resonance imaging in monitoring rectal cancer response to neoadjuvant chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics 2012, 83:594-599.
78. Janssen M.H., Ollers M.C., van Stiphout R.G., et al. Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings. Radiotherapy and Oncology 2010, 94:151-155.
79. Goldberg N., Kundel Y., Purim O., et al. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study. Radiation Oncology 2012, 1(7):124.
80. Hatt M., van Stiphout R., le Pogam A., Lammering G., Visvikis D., Lambin P. Early prediction of pathological response in locally advanced rectal cancer based on sequential (18)F-FDG PET. Acta Oncologica 2012, 10.3109/0284186X.2012.702923.
81. Perez R.O., Habr-Gama A., Gama-Rodrigues J., et al. Accuracy of PET/CT and clinical assessment in the detection of complete rectal tumor regression following neoadjuvant chemoradiation. Long-term results of a prospective trial (NCT00254683). Cancer 2011, 118:3501-3511.
82. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
83. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice. Oncology 2006, 3:24-40.
84. Cecchin E., Agostini M., Pucciarelli S., et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics Journal 2011, 11:214-226.
85. Toffoli G., Cecchin E., Gasparini G., et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2010, 28:866-871.
86. Toffoli G., D'Andrea M.R., Gasparini G. Irinotecan in the adjuvant treatment of colon cancer: is the story finished or does personalized therapy open new opportunities?. Journal of Clinical Oncology 2010, 28:e199.
87. Rodel C., Grabenbauer G.G., Papadopoulos T., et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. International Journal of Radiation Oncology, Biology, Physics 2002, 52:294-303.
88. Nyati M.K., Morgan M.A., Feng F.Y., Lawrence T.S. Integration of EGFR inhibitors with radiochemotherapy. Nature Reviews Cancer 2006, 6:876-885.
89. Milas L., Fang F.M., Mason K.A., et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. International Journal of Radiation Oncology, Biology, Physics 2007, 67:568-572.
90. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer 2008, 8:592-603.
91. Kerbel R.S., Yu J., Tran J., et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer and Metastasis Reviews 2001, 20:79-86.
92. Miller K.D., Sweeney C.J., Sledge G.W. Can tumor angiogenesis be inhibited without resistance?. EXS 2005, 94:95-112.
93. Mancuso M.R., Davis R., Norberg S.M., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. Journal of Clinical Investigation 2006, 116:2610-2621.
94. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology 2008, 26:1810-1816.
95. Grothey A., Sugrue M.M., Purdie D.M., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). Journal of Clinical Oncology 2008, 26:5326-5334.
96. Morelli M.P., Cascone T., Troiani T., et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Annals of Oncology 2005, 16(Suppl. 4):iv61-iv68.
97. Cao Y., Arbiser J., D'Amato R.J., et al. Forty-year journey of angiogenesis translational research. Science Translation Medicine 2011, 3(114). 114rv3.
98. Gasparini G., Gattuso D., Morabito A., et al. Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colonrectal cancer. The Oncologist 2005, 10:710-717.
99. Tortora G., Ciardiello F., Gasparini G. Combined targeting of ErbB-and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nature Clinical Practice. Oncology 2008, 5:521-530.
100. Gasparini G., Longo R., Torino F., Toffoli G., Barone C. Tailored therapy of colorectal cancer: results, challenges and future directions. Cancer Journal 2005, 11:175-188.
101. Gasparini G., Longo R., Torino F., Gattuso D., Morabito A., Toffoli G. Is tailored therapy feasible in oncology?. Critical Reviews in Oncology/Hematology 2006, 57:79-101.
102. Rau B., Sturm I., Lage H., et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. Journal of Clinical Oncology 2003, 21:3391-3401.
103. Begg A.C., Stewart F.A., Vens C. Strategies to improve radiotherapy with targeted drugs. Nature Reviews Cancer 2011, 11:239-253.
104. Sennino B., Ishiguro-Oonuma T., Wei Y., et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discovery 2012, 2:270-287.
105. Ding S., Merkulova-Rainon T., Han Z.C., Tobelem G. HGF receptor upregulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 2003, 101:4816-4822.
106. De Bacco F., Luraghi P., Medico E., et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. Journal of the National Cancer Institute 2011, 103:645-661.
107. Birkenkamp-Demtroder K., Olesen S.H., Sørensen F.B., et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005, 54:374-384.
108. Hong T.S., Clark J.W., Haigis K.M. Cancers of the colon and rectum: identical or fraternal twins?. Cancer Discovery 2012, 2:117-121.
109. Minoo P., Zlobec I., Peterson M., Terracciano L., Lugli A. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. International Journal of Oncology 2010, 37:707-718. 10.3892/ijo_00000720.
110. Li J.N., Zhao L., Wu J., et al. Differences in gene expression profiles and carcinogenesis pathways between colon and rectal cancer. Journal of Digestive Disease 2012, 13:24-32. 10.1111/j.1751-2980.2011.00551.x.
111. Patel U.B., Taylor F., Blomqvist L., et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. Journal of Clinical Oncology 2011, 29:3753-3760.
112. Giralt J., de las Heras M., Cerezo L., et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiotherapy and Oncology 2005, 74:101-108.
113. Kim J.S., Kim J.M., Li S., et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics 2006, 66:195-200.
114. Toiyama Y., Inoue Y., Saigusa S., et al. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. Clinical Oncology (Royal College of Radiologists) 2010, 22:272-280.
115. Carlomagno C., Pepe S., D'Armiento F.P., et al. Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Oncology 2010, 78:369-375.
116. Zlobec I., Vuong T., Compton C.C., et al. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. British Journal of Cancer 2008, 98:450-456.
117. Debucquoy A., Goethals L., Libbrecht L., et al. Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study. International Journal of Colorectal Disease 2009, 24:129-138.
118. Chang H.J., Jung K.H., Kim D.Y., et al. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Human Pathology 2005, 36:364-371.
119. Kikuchi M., Mikami T., Sato T., et al. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. British Journal of Cancer 2009, 101:116-123.
120. Negri F.V., Campanini N., Camisa R., et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. British Journal of Cancer 2008, 98:143-147.
121. Edden Y., Wexner S.D., Berho M. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma. Colorectal Disease 2012, 14:555-561. 10.1111/j.1463-1318.2011.02697.x.
122. Bertolini F., Bengala C., Losi L., et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics 2007, 68:1455-1461.
123. Huerta S., Hrom J., Gao X., et al. Tissue microarray constructs to predict a response to chemoradiation in rectal cancer. Digestive and Liver Disease 2010, 42:679-684.
124. Kim K., Chie E.K., Wu H.G., et al. High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. International Journal of Colorectal Disease 2011, 26:1019-1023.
125. Ho-Pun-Cheung A., Assenat E., Bascoul-Mollevi C., et al. A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. Pharmacogenomics Journal 2011, 11:437-443. 10.1038/tpj.2010.62.
126. Garcia-Aguilar J., Chen Z., Smith D.D., et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Annals of Surgery 2011, 254:486-492.
127. Conradi L.C., Bleckmann A., Schirmer M., et al. Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. Annals of Surgical Oncology 2011, 18:2442-2452. 10.1245/s10434-011-1608-4.
128. Stoehlmacher J., Goekkurt E., Mogck U., et al. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Cancer Letters 2008, 272:221-225.
129. Páez D., Salazar J., Paré L., et al. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. International Journal of Radiation Oncology, Biology, Physics 2011, 81:1319-1327.
130. Spindler K.L., Nielsen J.N., Lindebjerg J., Lindebjerg J. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. Diseases of the Colon and Rectum 2007, 50:1363-1369.
131. Hur H., Kang J., Kim N.K., et al. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. International Journal of Radiation Oncology, Biology, Physics 2011, 81:669-676.
132. Chiorean E.G., Sanghani S., Schiel M.A., et al. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. Cancer Chemotherapy and Pharmacology 2012, 18. 10.1007/s00280-012-1883-1.
133. Balboa E., Duran G., Lamas M.J., et al. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. Pharmacogenomics 2010, 11:747-761.
134. Lamas M.J., Duran G., Gomez A., et al. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. International Journal of Radiation Oncology, Biology, Physics 2012, 82:138-144.
135. Villafranca E., Okruzhnov Y., Dominguez M.A., et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. Journal of Clinical Oncology 2001, 19:1779-1786.
136. Tan B.R., Thomas F., Myerson R.J., et al. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. Journal of Clinical Oncology 2011, 29:875-883.
137. Terrazzino S., Agostini M., Pucciarelli S., et al. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics 2006, 16:817-824.
138. Luna-Perez P., Segura J., Alvarado I., Labastida S., Santiago-Payan H., Quintero A. Specific c-K-ras gene mutations as a tumorresponse marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Annals of Surgical Oncology 2000, 7:727-731.
139. Zauber N.P., Marotta S.P., Berman E., et al. Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma. International Journal of Radiation Oncology, Biology, Physics 2009, 74:472-476.
140. Kim S.Y., Shim E.K., Yeo H.Y., et al. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. International Journal of Radiation Oncology, Biology, Physics 2012, 10.1016/j.ijrobp.2012.03.048.
141. Gaedcke J., Grade M., Jung K., et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiotherapy and Oncology 2010, 94:76-81.
142. Grimminger P.P., Danenberg P., Dellas K., et al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clinical Cancer Research 2011, 17:3469-3477.
143. Bengala C., Bettelli S., Bertolini F., et al. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. British Journal of Cancer 2010, 103:1019-1024.
144. Grade M., Gaedcke J., Wangsa D., et al. Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy. Cancer Genetics and Cytogenetics 2009, 193:19-28.
145. Chen Z., Liu Z., Li W., et al. Chromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancer. Genes, Chromosomes and Cancer 2011, 50:689-699.
146. Nishioka M., Shimada M., Kurita N., et al. Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer. Cancer Genomics Proteomics 2011, 8:87-92.
147. Ghadimi B.M., Grade M., Difilippantonio M.J., et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. Journal of Clinical Oncology 2005, 23:1826-1838.
148. Rimkus C., Friederichs J., Boulesteix A.L., et al. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clinical Gastroenterology and Hepatology 2008, 6:53-61.
149. Kim I.J., Lim S.B., Kang H.C., et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Diseases of the Colon and Rectum 2007, 50:1342-1353.
150. Brettingham-Moore K.H., Duong C.P., Greenawalt D.M., et al. Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma. Clinical Cancer Research 2011, 17:3039-3047.
151. Watanabe T., Komuro Y., Kiyomatsu T., et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Research 2006, 66:3370-3374.
152. Allal A.S., Kahne T., Reverdin A.K., Lippert H., Schlegel W., Reymond M.A. Radioresistance-related proteins in rectal cancer. Proteomics 2004, 4:2261-2269.
153. Smith F.M., Gallagher W.M., Fox E., et al. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Annals of Surgery 2007, 245:259-266.